Regression of intracranial meningioma following treatment with nivolumab: Case report and review of the literature
2017; Elsevier BV; Volume: 37; Linguagem: Inglês
10.1016/j.jocn.2016.11.011
ISSN1532-2653
AutoresEfrat Gelerstein, Assaf Berger, Tali Jonas‐Kimchi, Ido Strauss, Andrew A. Kanner, Deborah T. Blumenthal, Maya Gottfried, Nevo Margalit, Zvi Ram, Tal Shahar,
Tópico(s)Glioma Diagnosis and Treatment
ResumoAbstract The treatment of refractory meningiomas remains a challenge for both neurosurgeons and neuro-oncologists. There have been no clinical reports of the use or effects of anti-PD-1 therapy in patients with meningioma. We describe a patient whose intracranial meningioma decreased significantly in size after treatment with nivolumab, a monoclonal antibody targeting PD-1, for a concomitant advanced lung cancer. This is the first clinical report suggesting that antibodies targeting PD-1 are effective in treating meningioma. It should encourage further research into the use of checkpoint inhibitors in meningioma.
Referência(s)